Clinical Trials Results - National Cancer Institute

In English \| En español

Search


	Clinical Trials Search Results

Page Options

E-Mail This Search

Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 44 for your search:

Cancer Type/Condition:  Bladder cancer
Stage/Subtype:  recurrent bladder cancer
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Phase III Randomized Study of Intravesical Gemcitabine Hydrochloride Immediately After Transurethral Resection of the Bladder Tumor in Patients With Newly Diagnosed or Recurrent Superficial Transitional Cell Bladder Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0337, S0337, NCT00445601

Phase III Randomized Study of Gemcitabine Hydrochloride and Cisplatin With Versus Without Bevacizumab in Patients With Advanced Transitional Cell Carcinoma of the Urinary Tract

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-90601, CALGB-90601, NCT00942331

Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: WBPDT-577-04, NCT00322699

Phase I/II Study of E7389 in Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Renal Insufficiency

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CCC-PHII-75, 7435, NCI-7435, NCT00365157

Phase I & II Trial of Intravesicular Abraxane for Treatment-Refractory Bladder Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: AAAC1114, NCT00583349

Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDX1401-01, NCT00948961

Phase II Study of Fluorouracil, Leucovorin Calcium, Gemcitabine, and Cisplatin in Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: NCI
Protocol IDs: MDA-ID-030111, NCT00082706

Phase II of Study Neoadjuvant Cisplatin, Bevacizumab, and Gemcitabine Hydrochloride Followed By Radical Cystectomy and Adjuvant Bevacizumab and Paclitaxel in Patients With Muscle-Invasive, Nonmetastatic, Resectable Transitional Cell Carcinoma of the Bladder

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: MUSC-AVF-3312, 100892, MUSC-HR-15537, GENENTECH-AVF-3312, NCT00268450, MUSC-CTO-100892

Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FER-GU-004, NCT00350025

10.

Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2005.145, NCT00393796

11.

Phase II Pilot Study of Irradiated Allogeneic Related Donor Lymphocyte Infusion in Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187

12.

Phase II Study of Pazopanib Hydrochloride in Patients With Metastatic Urothelial Cancer

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC0553, 7661, MC0553, NCT00471536

13.

Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0620, NCT00506155

14.

Phase II Randomized Study of Docetaxel With Versus Without Vandetanib in Patients With Previously Treated Stage IV Transitional Cell Carcinoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: DFCI-06116, FHCRC-6451, UWCC-UW-6451, UWCC-07-5533-H/D, 06-116, NCT00378794

15.

Phase II Pilot Study of Tamoxifen Citrate in Patients With Metastatic Transitional Cell Carcinoma of the Bladder That Progressed on Prior Platinum-Based Chemotherapy

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BCM-H16848, H#16848, NCT00589017

16.

Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2007.061, NCT00585689

17.

Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BC-07-01.CTIL, NCT00595088

18.

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA182-026, NCT00633789

19.

Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2007.097, NCT00645593

20.

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PDX-011, NCT00722553

21.

Phase II Trial of BIBW 2992 in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1200.26, NCT00748709

22.

Neoadjuvant Erlotinib (Tarceva) in Transitional Cell Carcinoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 2007-0704, NCT00749892

23.

Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection

Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MCC-15441, IRB 10718, NCT00751140

24.

Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2007-0933, NCT00756639

25.

Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy

Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: GRID, NCT00765570

Select All on Page

Help with Results

A Service of the National Cancer Institute